Tag Archive for: BrainTransporter platform

MoA of BioArtic's brain transporter technology that improved antibody uptake 70-fold in preclinical testsBioArctic AB
Neurodegeneration

Novartis secures US$30m+ licence option from BioArctic

Following the commercial launch of BioArctic AB’s Alzheimer’s antibody lecanemab, the Swedish company has announced a new deal: it will receive an upfront payment of US$30m, granting the Swiss company access to BioArctic’s BrainTransporter platform to transport therapeutics for neurodegeneration across the blood-brain barrier

Read more